Literature DB >> 8513522

Prolongation of epidural bupivacaine analgesia with glycerin.

H King1, C S Xiao, D J Wooten.   

Abstract

Glycerin has been used as a drug carrier/depot, but never with local anaesthetics. This study was an attempt to use the slow drug release mechanism to prolong the anaesthetic effects of bupivacaine in epidural block. Twenty-seven adults with cancer pain were prospectively selected according to their primary lesions and problems, but their allocation to study groups was randomized. Group I (n = 13), received 5 ml bupivacaine, 0.125% in normal saline via a previous implanted epidural catheter. When the pain returned to its original intensity, the same amount of the same strength anaesthetic dissolved in 50% glycerin was given via the same catheter. Group II (n = 14) received the same solutions, but in the reverse order. Also five patients in each group received plain 50% glycerin prior to administration of the anaesthetic solutions to serve as controls. The pharmacological effects were assessed by the blinded observers. Analgesia produced with glycerin solution was prolonged compared with the saline solution (12.2 vs 7.2 and 11.6 vs 7.4 hr, P < 0.01). The order of giving the solution did not produce any differences. Plan 50% glycerin did not produce analgesic effects. Neither motor blockade nor other adverse effects or complications were observed in either group. It was concluded that 0.125% bupivacaine in 50% glycerin administered epidurally is not neurotoxic. The prolongation of analgesia observed is attributed to the slow release of bupivacaine from the glycerin base which functions as drug depot. In addition to relief of chronic pain, this novel approach may have other clinical applications such as the relief of labour or postoperative pain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513522     DOI: 10.1007/BF03009512

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  17 in total

1.  QUALITY OF EPIDURAL BLOCKADE. I. INFLUENCE OF PHYSICAL FACTORS.

Authors:  P R BROMAGE; M F BURFOOT; D E CROWELL; R T PETTIGREW
Journal:  Br J Anaesth       Date:  1964-06       Impact factor: 9.166

2.  Neurological complications following the use of continuous extradural analgesia with bupivacaine.

Authors:  N M Dunne; W J Kox
Journal:  Br J Anaesth       Date:  1991-05       Impact factor: 9.166

3.  Prolongation of canine epidural anesthesia by liposome encapsulation of lidocaine.

Authors:  T Mashimo; I Uchida; M Pak; A Shibata; S Nishimura; Y Inagaki; I Yoshiya
Journal:  Anesth Analg       Date:  1992-06       Impact factor: 5.108

4.  [Risks in postoperative pain therapy using a peridural catheter in a normal general ward].

Authors:  C Maier; J Wawersik; H Wulf
Journal:  Anasth Intensivther Notfallmed       Date:  1986-04

5.  Evaluation of the use of visual analogue scale in Chinese patients.

Authors:  C Aun; Y M Lam; B Collett
Journal:  Pain       Date:  1986-05       Impact factor: 6.961

6.  Injection of the pterygopalatine fossa with glycerin for posterior epistaxis.

Authors:  C Z Weingarten
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1972 Jul-Aug

7.  Responses of laryngeal tissue to granular teflon in situ.

Authors:  R B Lewy
Journal:  Arch Otolaryngol       Date:  1966-04

8.  Studies of the larynx after teflon injection.

Authors:  F R Kirchner; P S Toledo; D J Svoboda
Journal:  Arch Otolaryngol       Date:  1966-04

9.  Glycerol and hyperosmolar nonketotic coma.

Authors:  D E Oakley; P P Ellis
Journal:  Am J Ophthalmol       Date:  1976-04       Impact factor: 5.258

10.  Spinal anesthesia: significant prolongation of the pharmacologic effect of tetracaine with lipid solution of the agent.

Authors:  L Langerman; E Golomb; S Benita
Journal:  Anesthesiology       Date:  1991-01       Impact factor: 7.892

View more
  1 in total

Review 1.  Management strategies for chronic pain.

Authors:  D M Justins
Journal:  Ann Rheum Dis       Date:  1996-09       Impact factor: 19.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.